Cigna · Vutrisiran ATTR Cm · US health-plan appeal rights

Vutrisiran ATTR Cm denied due to quantity / dose limits by Cigna?

Q: How long do I have to appeal a Cigna Vutrisiran ATTR Cm denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna Amvuttra (Vutrisiran) for ATTR-CM

The Cigna angle on Vutrisiran ATTR Cm

## Why Cigna Limits Vutrisiran (ATTR-CM) Quantities — and How to Appeal

Vutrisiran (Amvuttra) is FDA-approved for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Cigna imposes quantity limits on vutrisiran that align with its interpretation of the FDA-approved dosing schedule. A quantity-limit denial typically occurs when the dispensed or requested quantity — number of vials, syringes, or administration intervals — exceeds the limit defined in Cigna's coverage policy for a given dispensing period. These limits are sometimes set narrowly and do not account for administrative or clinical nuances that a prescriber, working from the FDA label, would recognize.

## Why This Denial Is Appealable

Quantity-limit policies must be clinically justified and consistently applied. Under ACA §2719, you have the right to a full internal appeal and then an independent external review. Under ERISA §503 (for employer-sponsored plans), the plan must provide a full-and-fair review. The external-review window is typically available for approximately four months after a final internal denial, and expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health.

For ATTR-CM — a progressive, life-threatening condition — delays caused by quantity-limit disputes are clinically significant and strengthen the case for expedited review.

## What to Gather

Diagnosis confirmation: Cardiologist records, nuclear imaging, biopsy, or genetic testing confirming ATTR-CM.
Current prescription and administration records: The prescriber's order, administration schedule, and any pharmacy or infusion records showing the quantity ordered and the clinical basis.
FDA prescribing label: Obtain the current full prescribing information for vutrisiran directly from the FDA website. The approved dosing regimen in the label is the clinical standard against which Cigna's limit should be measured.
Prescriber medical-necessity letter: A letter from your cardiologist confirming that the quantity ordered is consistent with the FDA-approved labeling and necessary for your treatment regimen.
Cigna's quantity-limit policy: Request Cigna's written quantity-limit criteria for vutrisiran so your appeal addresses each requirement explicitly.

## Criteria-Mapping Structure

For each quantity-limit criterion Cigna applies, provide a direct clinical response:

> Cigna quantity-limit criterion: [paste verbatim from policy] > Supporting evidence: [FDA label dosing language, prescription order, or cardiologist note confirming consistency]

## Timeline

File your internal appeal as soon as possible after receiving the denial — confirm the exact deadline in your denial letter. Request expedited review in writing given the severity of ATTR-CM. After a final internal denial, file for external review promptly to preserve your rights within the approximately four-month window.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Vutrisiran ATTR Cm

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.